30% pharmacy co-pay risk: why UAE medicines may look different after a refill

A medicine refill may look different because a pharmacy has dispensed an approved equivalent with the same active ingredient, strength and dosage form, a change that can affect adherence, claims and patient complaints in the UAE.

IOL reported on 2 September 2026 that South Africa's Department of Health had moved to reassure public-sector patients after changes in tablet colour, shape, packaging or manufacturer. The department said approved alternatives can carry the same therapeutic benefit when they meet regulatory and quality standards. For UAE operators, the story is less about South Africa and more about what happens at the pharmacy counter when a patient thinks the wrong product has been supplied.

Dubai pharmacies need a refill script

In Dubai, the first operational burden sits with Dubai Health Authority (DHA)-licensed pharmacies and clinics. A patient seeing a different box, blister or tablet should trigger a standard check: active ingredient, strength, route, dosage form, expiry date and prescription instructions. The pharmacist should document the counselling note in the dispensing record where the pharmacy system allows it.

The financial risk is also visible. The UAE Government portal states that medication co-payments are capped at 30%, with an annual cap of AED 1,500, for the relevant basic cover rules. A cheaper equivalent may reduce the patient's immediate payment, while a branded choice outside a reference price or formulary can create a balance bill or a rejected claim.

Co-payments for medications are capped at 30 per cent, with an annual cap of AED 1,500. — UAE Government portal

Clinic managers should not leave this to individual pharmacist judgement. The practical control is a two-line explanation printed on refill labels or sent by SMS when the manufacturer changes: the active ingredient is unchanged, and the patient should contact the pharmacy before stopping treatment. That matters most for chronic prescriptions in diabetes, hypertension, cardiac disease, epilepsy and psychiatric care.

Abu Dhabi already made generics a payer issue

Department of Health Abu Dhabi (DOH) introduced a generic dispensing mechanism with reference reimbursement prices from 1 September 2018. DOH said patients could choose between a brand and a generic medicine, but they would pay the difference between the reference price and the selected medicine price where applicable. Single-source medicines and narrow therapeutic window medicines were excluded from the DOH formulary list.

That makes appearance change a finance issue for Daman and Thiqa workflows as well as a pharmacy issue. Thiqa says the Abu Dhabi government programme for UAE nationals has been managed by Daman since 2008. When a member receives a different pack, the claims team needs the drug code, generic name, package price and formulary status before treating the case as a dispensing error.

Abu Dhabi providers can also point staff and patients to the DOH approved drug search, which lets users search by brand name, generic name or drug code. That is more useful than comparing colour or shape, because manufacturers can use different excipients, tablet designs and packaging for the same molecule.

What operators should do this month

The northern emirates are mainly a Ministry of Health and Prevention (MOHAP) and federal product-registration question, with the Emirates Drug Establishment now central to medical product oversight under Federal Decree-Law No. 38 of 2024. The UAE also has Tatmeen, launched nationally in 2023, to track pharmaceutical products through factories, distributors, pharmacies and consumers.

Operators should convert the issue into a short control list:

• Train pharmacy staff to compare active ingredient, strength and dosage form before answering patient queries.
• Flag high-risk medicines where appearance changes require pharmacist counselling before handover.
• Tell billing teams to check formulary and reference price fields before resubmitting rejected medicine claims.
• Use Tatmeen or approved drug searches when authenticity or registration is the concern.

Patients should not stop a medicine because a refill looks unfamiliar. They should call the dispensing pharmacy, check the label against the prescription and ask whether the product is a generic or alternative manufacturer. Clinics should make that instruction part of discharge counselling and chronic-care follow-up.

For provider verification, patients and operators can use the UAE Open Healthcare Directory to find licensed pharmacy providers across Dubai, Abu Dhabi and the northern emirates.